Learn more about the factors that may impact how you operationalize your treatment center.
Understand the treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI) patient populations in your community and how many appropriate patients you anticipate seeing weekly in your treatment center
Consider which room or designated area in your treatment center can be used as a dedicated space for patients taking SPRAVATO®, including a treatment chair where a patient can comfortably sit during the 2-hour monitoring period
Because SPRAVATO® is a Schedule III controlled substance, your treatment center will be required to store and dispose the product appropriately. Ensure that SPRAVATO® is kept in a secure place per state and federal regulations. Product dispensed by a pharmacy for a specific patient must be administered within 14 days after receipt by the treatment center
Examples of how a SPRAVATO® treatment space may be set up
Multiple treatment chairs in a shared space
Single treatment chair in a dedicated space
For illustrative purposes only. Not intended to represent a promise, guarantee, or legal advice by Janssen Pharmaceuticals, Inc., about practice efficiencies.
REMS=Risk Evaluation and Mitigation Strategy.
